5th November 2020 Product update: rapidmicrobiology staff writer
Creative Diagnostics Supports COVID-19 Testing with Antigen Lateral Flow Assay Development
Creative Diagnostics are now offering a range of products for COVID-19 antigen lateral flow assay (LFA) development. This includes SARS-CoV-2 nucleoprotein antibody pairs for rapid COVID-19 antigen assays and SARS-CoV-2 antigen extraction buffer tubes.
Antigen-based assays are suitably inexpensive and can be rapidly mass-produced, but sufficient diagnostic accuracy requires highly optimized antibodies and assay conditions.
Creative Diagnostics team has tested hundreds of anti-nucleocapsid antibody pairs and can recommend to clients the best pair for further development of a SARS-CoV-2 antigen LFA.
Additionally, Creative Diagnostics also offers SARS-CoV-2 antigen extraction buffer tubes that can be used as packing supplies for SARS-CoV-2 antigen extraction. The global COVID-19 pandemic has created an urgent demand for accurate, rapid point of care testing.
SARS-CoV-2 antigen buffer tubes are also designed by Creative Diagnostics experts to extract SARS-CoV-2 antigen from the nasopharyngeal swab, which can be used for SARS-CoV-2 rapid antigen test development and production.
It's noted that the slim tube design of these plastic tubes also reduces the need for the amount of extraction buffer, thereby increasing the concentration of the virus antigen in the sample and improving the positive detection rate of virus antigen.
"We know that many scientists are still diligently pursuing their research, particularly those focused on COVID-19, and to meet their growing needs, we've provided a series of additional SARS-CoV-2 related products and services to ensure that our customers have the supplies they need to continue their research programs. We are proud to support them in these efforts," said Prof. Mike Knuth, M.D., the chief scientific officer of the R&D department of Creative Diagnostics.
If you want to know more information about SARS-CoV-2 related testing products or other coronavirus research materials, please contact Creative Diagnostics at +1-631-619-7922 or rapidly via the 'Request Information' button provided below.
Date Published: 5th November 2020
Source article link: View
Note: This content has been edited by a rapidmicrobiology staff writer for style and content.
Creative Diagnostics Launches SARS-CoV-2 Immunoassay
Evaluate Vaccination with Recombinant SARS-CoV-2